| Year |
Citation |
Score |
| 2020 |
Wigle TJ, Blackwell DJ, Schenkel LB, Ren Y, Church WD, Desai HJ, Swinger KK, Santospago AG, Majer CR, Lu AZ, Niepel M, Perl NR, Vasbinder MM, Keilhack H, Kuntz KW. Abstract 506: A bespoke screening platform to study mono(ADP-ribosylation) Cancer Research. 80: 506-506. DOI: 10.1158/1538-7445.Am2020-506 |
0.303 |
|
| 2017 |
Schenkel LB, DiMauro EF, Nguyen HN, Chakka N, Du B, Foti RS, Guzman-Perez A, Jarosh M, La DS, Ligutti J, Milgram BC, Moyer BD, Peterson EA, Roberts J, Yu VL, et al. Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 28684121 DOI: 10.1016/J.Bmcl.2017.06.054 |
0.304 |
|
| 2017 |
Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio CM, Butler JR, Chu-Moyer MY, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT, Guzman-Perez A, ... ... Schenkel LB, et al. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust In Vivo Activity. Journal of Medicinal Chemistry. PMID 28324649 DOI: 10.1021/Acs.Jmedchem.6B01850 |
0.328 |
|
| 2016 |
DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Feric Bojic E, Foti RS, Fremeau RT, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, ... ... Schenkel LB, et al. Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. Journal of Medicinal Chemistry. PMID 27441383 DOI: 10.1021/Acs.Jmedchem.6B00425 |
0.405 |
|
| 2015 |
Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Schenkel LB, Vaida KR, Andrews P, Bak A, Be X, Beltran PJ, Bush TL, Chaves MK, et al. Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines. Journal of Medicinal Chemistry. PMID 25970324 DOI: 10.1021/Acs.Jmedchem.5B00183 |
0.319 |
|
| 2013 |
Yu V, Pistillo J, Archibeque I, Han Lee J, Sun BC, Schenkel LB, Geuns-Meyer S, Liu L, Emkey R. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings. Experimental Hematology. 41: 491-500. PMID 23340136 DOI: 10.1016/J.Exphem.2013.01.005 |
0.31 |
|
| 2012 |
Nguyen HN, Cee VJ, Deak HL, Du B, Faber KP, Gunaydin H, Hodous BL, Hollis SL, Krolikowski PH, Olivieri PR, Patel VF, Romero K, Schenkel LB, Geuns-Meyer SD. Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones. The Journal of Organic Chemistry. 77: 3887-906. PMID 22458369 DOI: 10.1021/Jo3000628 |
0.375 |
|
| 2011 |
Schenkel LB, Huang X, Cheng A, Deak HL, Doherty E, Emkey R, Gu Y, Gunaydin H, Kim JL, Lee J, Loberg R, Olivieri P, Pistillo J, Tang J, Wan Q, et al. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. Journal of Medicinal Chemistry. 54: 8440-50. PMID 22087750 DOI: 10.1021/Jm200911R |
0.302 |
|
| 2011 |
Peterson EA, Andrews PS, Be X, Boezio AA, Bush TL, Cheng AC, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Harmange JC, Kim JL, Mullady EL, ... ... Schenkel LB, et al. Discovery of triazine-benzimidazoles as selective inhibitors of mTOR. Bioorganic & Medicinal Chemistry Letters. 21: 2064-70. PMID 21376583 DOI: 10.1016/J.Bmcl.2011.02.007 |
0.306 |
|
| 2011 |
Liu L, Yu V, Pistillo J, Lee J, Schenkel LB, Geuns-Meyer S, Archibeque I, Sinclair A, Emkey R, Molineux G. New Insights on Assessing Intra-Family Selectivity for Jak2 Inhibitors Blood. 118: 5150-5150. DOI: 10.1182/Blood.V118.21.5150.5150 |
0.329 |
|
| 2010 |
Cee VJ, Schenkel LB, Hodous BL, Deak HL, Nguyen HN, Olivieri PR, Romero K, Bak A, Be X, Bellon S, Bush TL, Cheng AC, Chung G, Coats S, Eden PM, et al. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor. Journal of Medicinal Chemistry. 53: 6368-77. PMID 20684549 DOI: 10.1021/Jm100394Y |
0.303 |
|
| 2010 |
Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Patel VF, Be X, Bush TL, Chung G, Eden P, Huang L, et al. Abstract 5776: Discovery of AMG 900, a highly selective, orally bioavailable inhibitor of aurora kinases with efficacy in preclinical antitumor models and activity against multidrug-resistant cells Cancer Research. 70: 5776-5776. DOI: 10.1158/1538-7445.Am10-5776 |
0.319 |
|
| 2007 |
Tanuwidjaja J, Peltier HM, Lewis JC, Schenkel LB, Ellman JA. One-pot microwave-promoted synthesis of nitriles from aldehydes via tert-butanesulfinyl imines Synthesis. 3385-3389. DOI: 10.1055/S-2007-990805 |
0.498 |
|
| 2006 |
Guram AS, King AO, Allen JG, Wang X, Schenkel LB, Chan J, Bunel EE, Faul MM, Larsen RD, Martinelli MJ, Reider PJ. New air-stable catalysts for general and efficient suzuki-miyaura cross-coupling reactions of heteroaryl chlorides. Organic Letters. 8: 1787-9. PMID 16623551 DOI: 10.1021/Ol060268G |
0.406 |
|
| 2004 |
Schenkel LB, Ellman JA. Self-condensation of N-tert-butanesulfinyl aldimines: application to the rapid asymmetric synthesis of biologically important amine-containing compounds. Organic Letters. 6: 3621-4. PMID 15387563 DOI: 10.1021/Ol048458J |
0.569 |
|
| 2004 |
Schenkel LB, Ellman JA. Application of P,N-sulfinyl imine ligands to iridium-catalyzed asymmetric hydrogenation of olefins. The Journal of Organic Chemistry. 69: 1800-2. PMID 15058921 DOI: 10.1021/Jo035675+ |
0.502 |
|
| 2003 |
Schenkel LB, Ellman JA. Novel sulfinyl imine ligands for asymmetric catalysis. Organic Letters. 5: 545-8. PMID 12583765 DOI: 10.1021/Ol027468M |
0.506 |
|
| 2000 |
Li X, Schenkel LB, Kozlowski MC. Synthesis and resolution of a novel chiral diamine ligand and application to asymmetric lithiation-substitution Organic Letters. 2: 875-8. PMID 10768175 DOI: 10.1021/Ol9903133 |
0.354 |
|
| Show low-probability matches. |